Microbix Biosystems Inc. develops proprietary biological solutions for human health. The company shows strengths with a solid gross margin of 53.9% and a strong liquidity position, indicated by a current ratio of 6.89. However, concerns arise from negative EBITDA and net margins, suggesting ongoing operational challenges. The low market cap of $43.83M relative to its high gross margin may indicate undervaluation, but the negative return metrics raise questions about profitability and future growth potential. Overall, while liquidity is strong, profitability remains a significant hurdle.
Loading financial metrics...
Revenue fell 35.5% year-over-year from $22.7M to $14.7M. The decline has persisted for multiple quarters.
Gross profit margin declined from 57.7% to 46.1% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-5.4M over the last year, representing 36.6% of revenue.
Excellent liquidity with current ratio of 6.9x ensures operational stability.
Strong balance sheet with net cash position provides cushion for growth investments.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q3 (June 30, 2026)